Global Periodic Fever Syndromes Market Companies

Companies such as Novartis AG (Switzerland), Regeneron Pharmaceuticals Inc. (U.S.), Swedish Orphan Biovitrum AB (Sweden), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), are major players in periodic fever syndromes market.

In March 2025, Novartis initiated a Phase III clinical trial for Ilaris (canakinumab) targeting Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), and Hyperimmunoglobulinemia D Syndrome (HIDS). This non-interventional study aims to evaluate the safety and effectiveness of Ilaris in both adult and pediatric patients across multiple centers in Korea. In February 2025, The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Goflikicept (RPH-104), a novel heterodimeric hybrid protein capable of binding with high affinity to human IL-1β and IL-1α, for the treatment of CAPS. This designation is expected to facilitate the drug's development and expedite its review process

The countries covered in the periodic fever syndromes market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.